Protection against chemically induced liver injury is a recognized health function claim for health foods, and its determination relies on standardized in vivo studies that quantify biochemical and histopathological markers of hepatoprotection. Using validated animal models such as carbon tetrachloride (CCl4)-induced hepatotoxicity, accredited third-party laboratories measure serum ALT and AST activities, liver organ coefficients, and liver tissue pathology to establish whether a product provides meaningful protection against chemical liver damage. This article explains the testing principle, sample requirements, methodology, evaluation criteria, and regulatory applications of this determination for health food registration and product development.
Technical Overview
The protective effect of health foods against chemically induced liver injury, often referred to as auxiliary hepatoprotection, is a statutory health function claim evaluated under the Chinese health food regulatory framework. The core technical basis is the Technical Standards for Testing and Assessment of Health Food (2003 Edition) issued by the Ministry of Health, applied together with the GB 15193 series of national food safety standards for food toxicology testing. The determination is a controlled in vivo study: laboratory animals receive the test sample orally for 30 days, an acute chemical hepatotoxin is then administered to induce measurable liver injury, and the severity of injury in treated animals is compared with that of untreated challenged controls.
If animals receiving the test article show significantly reduced liver injury compared with the model control group, both biochemically and histopathologically, the sample is judged to possess a protective effect against chemically induced liver damage. Studies of this type must be performed by accredited third-party laboratories holding ISO/IEC 17025 accreditation, with animal housing, environmental control, and ethical review conforming to GB 14925 and related laboratory animal welfare standards.
Testing Principle
Hepatotoxins such as carbon tetrachloride are bioactivated in the liver to free-radical metabolites that peroxidize hepatocyte membranes, producing centrilobular necrosis and the leakage of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) into the bloodstream. A sample with hepatoprotective activity reduces membrane damage, blunts the elevation of serum transaminases, and mitigates histological lesions. These effects can be quantified objectively against blank and model control groups, providing the evidentiary basis for the function claim.
Testing Samples
The determination is applicable to finished health food products and to functional ingredients under development. Sample form determines the pretreatment procedure, and representative, well-characterized material must be supplied to guarantee the validity of the study.
Finished Products
- Tablets, caplets, and chewable formulations, crushed and homogenized before dosing
- Hard capsules and softgels, with contents emptied or the intact unit homogenized as appropriate
- Granules, powders, and tea-bag formulations
- Oral liquids, functional beverages, and fermented liquid products, dosed directly or concentrated according to dose-setting requirements
Raw Materials and Functional Ingredients
- Botanical extracts, including silymarin-rich milk thistle extract, Schisandra chinensis extract, and other traditionally used liver-supporting plants
- Fungal and microbial fermentation products
- Protein hydrolysates, bioactive peptides, and amino acid complexes
- Vitamin, cofactor, and mineral-based formulations intended for liver function support
Submission Requirements
- Sufficient quantity, typically 500 g to 1 kg or the equivalent volume, to cover all dose groups, retention samples, and contingencies
- Documented recommended human daily intake, which anchors the animal dose design
- Full composition information, physical form, shelf life, and recommended storage conditions
- A representative production or pilot-scale batch, accompanied by a declaration that the tested sample corresponds to the formulation intended for market
Testing Items
Primary Biochemical Indicators
- Serum ALT (alanine aminotransferase, GPT) activity
- Serum AST (aspartate aminotransferase, GOT) activity
Auxiliary Biochemical Indicators
- Total bilirubin (T-Bil) and bilirubin fractions where required
- Alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT)
- Albumin and total protein as markers of hepatic synthetic function
Organ and Morphological Indicators
- Liver organ coefficient, calculated as liver-to-body-weight ratio
- Histopathological examination of hematoxylin-eosin stained sections, with blinded scoring of hepatocyte degeneration, necrosis, ballooning, and inflammatory infiltration
Optional Mechanistic Markers
- Malondialdehyde (MDA) as an index of hepatic lipid peroxidation
- Reduced glutathione (GSH) and glutathione peroxidase (GSH-Px) activity in liver tissue
- Superoxide dismutase (SOD) activity in liver homogenate
Testing Methods
Animal Model Options
- Carbon tetrachloride (CCl4) model, the reference method: a single intraperitoneal dose of approximately 0.1 percent CCl4 in vegetable oil at 10 mL/kg body weight induces acute centrilobular injury, with sampling about 24 hours after challenge
- D-galactosamine (D-GalN) model: typically 600 to 800 mg/kg intraperitoneally, producing diffuse hepatocellular injury with a hepatitis-like pattern
- Alcohol (ethanol) model: repeated gavage of diluted ethanol over several weeks, suitable for chronic injury and steatosis-oriented product positioning
- Acetaminophen (APAP) model: a single dose in the range of 150 to 300 mg/kg, inducing oxidative and mitochondrial injury through reactive metabolite formation
Study Design and Dose Setting
Healthy adult mice, commonly 18 to 22 g, or rats are randomized into at least five groups with a minimum of 10 to 15 animals each: a blank control receiving vehicle only, an injury model control, and three dose groups. Dose levels are typically set at 5, 10, and 30 times the recommended human daily intake on a body-weight-converted basis, and a positive reference group using a recognized hepatoprotective agent may be included to monitor model responsiveness. The sample is administered daily by oral gavage, generally not exceeding 20 mL/kg, for 30 consecutive days, with body weight and food intake recorded throughout.
Experimental Procedure
- Acclimatization of animals for 3 to 7 days, followed by randomization and initiation of dosing
- Daily oral administration of the test sample at the assigned dose levels for 30 days
- Induction of liver injury shortly after the final dose using the selected chemical hepatotoxin
- Blood collection, typically 24 hours after challenge, followed by serum separation
- Determination of ALT and AST activities on an automatic biochemistry analyzer using validated kinetic methods
- Necropsy with liver weighing for organ coefficient calculation
- Fixation of liver tissue in neutral buffered formalin, paraffin embedding, sectioning, hematoxylin-eosin staining, and blinded pathological scoring
- Statistical analysis, normally analysis of variance with appropriate post-hoc comparisons of dose groups against the model control
Evaluation and Judgment Criteria
- Model validity: the model control group must show significantly elevated ALT and AST relative to the blank control, with histologically confirmed injury
- Protective effect: at least one dose group must demonstrate significantly lower ALT and/or AST than the model control, corroborated by significantly improved histopathology scores
- Safety consistency: body weight, food intake, and general condition must remain within normal limits, with no treatment-related adverse findings attributable to the sample itself
- Evidence integration: biochemical and histological results must be internally consistent for the function claim to be substantiated in a regulatory dossier
Applications
- Registration dossiers supporting the recognized claim of auxiliary protection against chemically induced liver injury under the national health food registration scheme
- Claim substantiation and dose-finding during formulation development and optimization
- Comparative efficacy screening of candidate botanical extracts, fermentation products, and finished formulations
- Substantiation documentation for labeling claims, marketing materials, and export dossiers in jurisdictions where hepatoprotective positioning is permitted
- Shelf-life programs verifying that the function-relevant activity of the product is retained through its intended storage period
FAQ
Which chemical model should be selected?
The CCl4 model is the default and most widely accepted basis for registration purposes. The D-GalN, alcohol, and acetaminophen models are selected when product positioning or the known mechanism of the active ingredient makes them more relevant, and the study protocol should clearly justify the model chosen.
How long does the determination take?
A standard 30-day mouse study, including acclimatization, dosing, biochemical analysis, histopathology, and reporting, typically requires six to eight weeks of laboratory work. Additional time should be planned for sample pretreatment, protocol finalization, and ethics approval.
How much sample needs to be submitted?
As a practical guide, 500 g to 1 kg, or the equivalent volume for liquid products, covers three dose groups, controls, retention samples, and contingencies. The testing laboratory confirms exact quantities after reviewing the recommended human intake and study design.
Do both ALT and AST have to decrease for a positive result?
No. Under the accepted judgment rules, a statistically significant reduction in one of the two transaminases, supported by improved histopathology relative to the model control, is sufficient to support the claim. Concurrent reductions in both markers strengthen the overall evidence package.
Are in vitro alternatives acceptable?
Hepatocyte-based cytotoxicity assays are valuable for early screening and mechanism studies, but the recognized health function claim currently requires in vivo determination with both biochemical and histopathological endpoints conducted under the applicable technical evaluation standards.
What credentials should the testing laboratory hold?
The study should be performed by accredited third-party laboratories with ISO/IEC 17025 accreditation covering the relevant test items, animal facilities compliant with GB 14925, and documented ethical approval obtained before animal work begins. Because regulatory technical requirements are periodically revised, sponsors should also confirm that the laboratory is applying the currently effective evaluation guideline.
